The SHL Perspective

Empowering Innovation

Maggie® is an easy-to-use, cartridge-based autoinjector built with SHL’s proprietary Needle Isolation Technology (NIT®). Requiring just two simple steps to operate, Maggie® opens  up pathways for larger fill  volumes and an enhanced  injection experience.

Learn more at the 2021 PDA Universe of Pre-Filled Syringes and Injection Devices virtual event | Oct 5-6

Maggie®

Transform your cartridge-based treatment with Maggie®, a two-step autoinjector built with SHL’s proprietary Needle Isolation Technology (NIT®).

Needle Isolation Technology

Close

NIT® is a unique safety solution that makes it possible for cartridges to function like traditional pre-filled syringes with staked needles. Cartridges support higher volume dosing and enable dual-chamber treatments to be built as easy-to-use autoinjectors.

Higher Volume Injections

Close

Maggie® is built with a 3mL standard ISO cartridge to support the growing trend for high-volume dosing with the emergence of biologics and biosimilars. Cartridges also offer a level of needle customization for subcutaneous or intramuscular injections.

Automated Preparation

Close

Maggie®’s NIT® sub-assembly includes a pre-attached needle. Users simply untwist the cap to attach the needle and open the fluid path. The needle cover automatically extends and the autoinjector automatically primes.

Easy 2-Step Handling

Close

Injection with Maggie® is completed with just two simple steps: uncap and inject. The autoinjector needle cover locks out after injection, shielding patients from being exposed to the needle before and after injection.

Intuitive Feedback

Close

Maggie®’s large viewing window makes it easier for patients to inspect the drug before and during injection. It also features continuous audible clicks during injection, resulting in an easier determination of dose completion.

Intuitive Feedback

Maggie®’s large viewing window makes it easier for patients to inspect the drug before and during injection. It also features continuous audible clicks during injection, resulting in an easier determination of dose completion.

Easy 2-Step Handling

Injection with Maggie® is completed with just two simple steps: uncap and inject. The autoinjector needle cover locks out after injection, shielding patients from being exposed to the needle before and after injection.

Automated Preparation

Maggie®’s NIT® sub-assembly includes a pre-attached needle. Users simply untwist the cap to attach the needle and open the fluid path. The needle cover automatically extends and the autoinjector automatically primes.

Higher Volume Injections

Maggie® is built with a 3mL standard ISO cartridge to support the growing trend for high-volume dosing with the emergence of biologics and biosimilars. Cartridges also offer a level of needle customization for subcutaneous or intramuscular injections.

Needle Isolation Technology

NIT® is a unique safety solution that makes it possible for cartridges to function like traditional pre-filled syringes with staked needles. Cartridges support higher volume dosing and enable dual-chamber treatments to be built as easy-to-use autoinjectors.

© 2021 SHL Medical AG. SHL, the SHL logo, and all other trademarks are property of SHL Medical AG and/or its affiliates.

Go to article: Home | Once more unto the (data) breachGo to article: In this issueGo to article: ContentsGo to article: SHL MedicalGo to article: SHL Medical Company Insight Go to article: Datwyler Company InsightGo to article: DatwylerGo to article: LabcorpGo to article: BriefingGo to article: Industry newsGo to article: The pharma industry briefingGo to article: Covid-19 executive briefing by GlobalDataGo to article: Mimotopes Company Insight Go to article: MimotopesGo to article: BaxterGo to article: Sukano Company InsightGo to article: SukanoGo to article: CommentGo to article: Use of off-label therapies increases the need for reliable clinical trial dataGo to article: Unmet needs remain in the neuroendocrine tumour treatment paradigmGo to article: Drinking alcohol raises risk of oesophageal and other cancersGo to article: Verder Company InsightGo to article: VerderGo to article: RegPakGo to article: Avery DennisonGo to article: In DepthGo to article: Pharma cybersecurity breaches to know and learn fromGo to article: The drugs treating alcoholism Go to article: In with the old: how an established vaccine is fuelling Covid-19 treatmentGo to article: How are hospitals tackling pharmaceutical pollution?Go to article: After Covid-19, mRNA technology aims to revolutionise the flu shotGo to article: Pushing for a UK genomics revolutionGo to article: MicronovaGo to article: Pfeiffer VacuumGo to article: HOF SonderanlagenbauGo to article: In DataGo to article: Data: pharma subsidiaries Go to article: Deals analysisGo to article: The pharma industry key listGo to article: Global markets and indicesGo to article: Macro-economic indicatorsGo to article: Macro-economic indicators (page 2)Go to article: EventsGo to article: Next issue